Start up. Grow up. Succeed.

News 2012

4SC Discovery and BioNTech announce exclusive research and license agreement for 4SC's TLR agonists for cancer immunotherapy

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer,

BioNTech AG Appoints Sean Marett as COO (Chief Operating Officer)

BioNTech AG, a pharmaceutical company based in Mainz, reports that it has successfully expanded its management team with the appointment of Sean Marettas COO.

SuppreMol releases positive interim Phase Ib/IIa results on SM101 in Primary Immune Thrombocytopenia (ITP) trials Data confirm excellent safety profile and therapeutic activity

SuppreMol GmbH, an autoimmune diseases specialist, today announced interim results of the Phase Ib/IIa clinical trial of SM101 to treat Primary Immune Thrombocytopenia (ITP).

SuppreMol releases positive interim Phase Ib/IIa results on SM101 in Primary Immune Thrombocytopenia (ITP) trials Data confirm excellent safety profile and therapeutic activity

SuppreMol GmbH, an autoimmune diseases specialist, today announced interim results of the Phase Ib/IIa clinical trial of SM101 to treat Primary Immune Thrombocytopenia (ITP).

JPT Peptide Technologies, IUCT and LEITAT Announce Collaboration on the Development of Novel Bio-focused Anticancer Therapies (NOBITAN)

JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of Bi-oNTech AG (Mainz, Germany), IUCT and LEITAT (Barcelona, Spain) announced today their collaboration on the joint development of an enhanced anticancer therapy based on the biofocused targeting of nucleoside analogs linked to small cyclic peptidomimetics.